Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DehydraTECH-estrogen is a preclinical-stage small molecule formulation being developed by Cannabis Delivery Sciences, a subsidiary of Lexaria Bioscience. It utilizes the proprietary DehydraTECH drug delivery platform, which is designed to improve the oral bioavailability, speed of onset, and taste of lipophilic active pharmaceutical ingredients. This specific formulation targets the estrogen receptor and is intended for the treatment of hormone-related conditions and dementia, leveraging the potential neuroprotective effects of estrogen. The DehydraTECH technology works by combining the drug with specific fatty acids and processing it to enhance intestinal absorption, potentially bypassing first-pass liver metabolism and providing a more efficient delivery route compared to traditional oral estrogens.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on DehydraTECH-estrogen.